Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

 KYMR – Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.
KYMR
$56.92
Name : Kymera Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $4,114,686,464.00
EPSttm : -3.49
finviz dynamic chart for KYMR
Kymera Therapeutics, Inc.
$56.92
1.09%
$0.63

Float Short %

12.62

Margin Of Safety %

Put/Call OI Ratio

0.41

EPS Next Q Diff

0.06

EPS Last/This Y

-0.44

EPS This/Next Y

-0.67

Price

56.88

Target Price

64.33

Analyst Recom

1.05

Performance Q

25.98

Relative Volume

0.44

Beta

2.33

Ticker: KYMR




22 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-09-08KYMR43.260.32999.992046
2025-09-09KYMR43.430.32999.992051
2025-09-10KYMR43.480.320.672052
2025-09-11KYMR46.220.320.012055
2025-09-12KYMR470.320.332073
2025-09-15KYMR47.280.320.002075
2025-09-16KYMR48.740.322.002075
2025-09-17KYMR48.120.323135755258130.318681318681322076
2025-09-18KYMR51.190.332.592162
2025-09-19KYMR49.10.370.012274
2025-09-22KYMR510.391.042152
2025-09-23KYMR50.850.410.132231
2025-09-24KYMR52.490.410.082258
2025-09-25KYMR53.750.400.082295
2025-09-26KYMR56.260.390.032329
2025-09-29KYMR58.520.370.402446
2025-09-30KYMR56.60.382.192528
2025-10-01KYMR54.690.401.432572
2025-10-02KYMR560.410.792625
2025-10-03KYMR57.920.420.472678
2025-10-06KYMR57.530.420.642768
2025-10-07KYMR56.910.412.432768
DateSymbolLastP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-09-08KYMR43.26-0.5-39.1-3.39
2025-09-09KYMR43.44-0.5-42.9-3.39
2025-09-10KYMR43.51-0.5-41.5-3.39
2025-09-11KYMR46.20-0.5-65.6-3.39
2025-09-12KYMR46.93-0.5-47.5-3.39
2025-09-15KYMR47.28-0.5-43.7-3.39
2025-09-16KYMR48.78-0.5-53.5-3.39
2025-09-17KYMR48.16-0.5-36.5-3.39
2025-09-18KYMR51.15-1.9-65.3-3.39
2025-09-19KYMR49.10-1.9-25.9-3.39
2025-09-22KYMR51.01-1.9-55.8-3.42
2025-09-23KYMR50.89-1.9-40.5-3.42
2025-09-24KYMR52.49-1.9-53.4-3.42
2025-09-25KYMR53.74-1.9-50.1-3.42
2025-09-26KYMR56.25-1.9-58.7-3.42
2025-09-29KYMR58.52-1.9-56.2-3.42
2025-09-30KYMR56.65-1.9-29.7-3.42
2025-10-01KYMR54.69-1.9-28.8-3.42
2025-10-02KYMR55.97-1.9-50.2-3.42
2025-10-03KYMR57.93-1.9-54.0-3.42
2025-10-06KYMR57.59-1.9-51.8-3.42
2025-10-07KYMR56.88-1.9-37.0-3.42
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-09-08KYMR7.7813.7712.94
2025-09-09KYMR7.7513.7712.94
2025-09-10KYMR7.7513.7712.94
2025-09-11KYMR7.7513.7713.88
2025-09-12KYMR7.7513.7713.83
2025-09-15KYMR7.9113.8713.83
2025-09-16KYMR7.6313.8713.83
2025-09-17KYMR6.9013.8713.83
2025-09-18KYMR6.9013.8713.83
2025-09-19KYMR6.9013.8713.82
2025-09-22KYMR6.9113.8713.82
2025-09-23KYMR6.9113.8713.82
2025-09-24KYMR6.9113.8713.82
2025-09-25KYMR6.9113.8712.62
2025-09-26KYMR6.9113.8712.62
2025-09-29KYMR6.9113.7112.62
2025-09-30KYMR6.9113.7112.62
2025-10-01KYMR6.9113.7112.62
2025-10-02KYMR6.9113.7112.62
2025-10-03KYMR6.9113.7112.62
2025-10-06KYMR6.917.5812.62
2025-10-07KYMR6.917.5812.62
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

-0.95

Avg. EPS Est. Current Quarter

-0.84

Avg. EPS Est. Next Quarter

-0.89

Insider Transactions

6.91

Institutional Transactions

7.58

Beta

2.33

Average Sales Estimate Current Quarter

19

Average Sales Estimate Next Quarter

17

Fair Value

Quality Score

26

Growth Score

26

Sentiment Score

74

Actual DrawDown %

38.1

Max Drawdown 5-Year %

-87.5

Target Price

64.33

P/E

Forward P/E

PEG

P/S

91.02

P/B

4.13

P/Free Cash Flow

EPS

-3.48

Average EPS Est. Cur. Y​

-3.42

EPS Next Y. (Est.)

-4.09

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-616.03

Relative Volume

0.44

Return on Equity vs Sector %

-53.5

Return on Equity vs Industry %

-39.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

-37
Kymera Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 218
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
stock quote shares  KYMR – Kymera Therapeutics, Inc. Stock Price stock today
news today  KYMR – Kymera Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch  KYMR – Kymera Therapeutics, Inc. yahoo finance google finance
stock history  KYMR – Kymera Therapeutics, Inc. invest stock market
stock prices KYMR premarket after hours
ticker KYMR fair value insiders trading